Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

(Immunity 49, 1148–1161.e1–e7; December 18, 2018) Due to an inadvertent author error, the STAR Methods and key resources table for the article listed the accession number for the two individual RNA-sequencing samples rather than the reference for the entire collection, which is GEO: GSE112865. The authors apologize for this error. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12Garris et al.ImmunityDecember 11, 2018In BriefAnti-PD-1 mAbs can induce sustained clinical responses in cancer but how they function in vivo remains incompletely understood. Garris et al. show that effective anti-PD-1 immunotherapy requires intratumoral dendritic cells (DCs) producing IL-12. Anti-PD-1 indirectly activates DCs through IFN-γ released from drug-activated T cells. Furthermore, agonizing the non-canonical NF-κB pathway activates DCs and enhances aPD-1 therapy in an IL-12-dependent manner. Full-Text PDF Open Archive